BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

158 related articles for article (PubMed ID: 37317905)

  • 41. Ph-negative non-Hodgkin's lymphoma occurring in chronic phase of Ph-positive chronic myelogenous leukemia is defined as a genetically different neoplasm from extramedullary localized blast crisis: report of two cases and review of the literature.
    Ichinohasama R; Miura I; Takahashi N; Sugawara T; Tamate E; Endoh K; Endoh F; Naganuma H; DeCoteau JF; Griffin JD; Kadin ME; Ooya K
    Leukemia; 2000 Jan; 14(1):169-82. PubMed ID: 10637493
    [TBL] [Abstract][Full Text] [Related]  

  • 42. The Polymorphisms in LNK Gene Correlated to the Clinical Type of Myeloproliferative Neoplasms.
    Chen Y; Fang F; Hu Y; Liu Q; Bu D; Tan M; Wu L; Zhu P
    PLoS One; 2016; 11(4):e0154183. PubMed ID: 27111338
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Feasibility of Qualitative Testing of BCR-ABL and JAK2 V617F in Suspected Myeloproliperative Neoplasm (MPN) Using RT-PCR Reversed Dot Blot Hybridization (RT-PCR RDB).
    Masykura N; Habibah U; Selasih SF; Gani S; Irawan C; Somoastro S; Handoyo Utomo AR
    Clin Lymphoma Myeloma Leuk; 2019 Apr; 19(4):220-227. PubMed ID: 30772299
    [TBL] [Abstract][Full Text] [Related]  

  • 44. CALR, JAK2, and MPL mutation profiles in patients with four different subtypes of myeloproliferative neoplasms: primary myelofibrosis, essential thrombocythemia, polycythemia vera, and myeloproliferative neoplasm, unclassifiable.
    Kim SY; Im K; Park SN; Kwon J; Kim JA; Lee DS
    Am J Clin Pathol; 2015 May; 143(5):635-44. PubMed ID: 25873496
    [TBL] [Abstract][Full Text] [Related]  

  • 45. The Prevalence of JAK2, MPL, and CALR Mutations in Chinese Patients With BCR-ABL1-Negative Myeloproliferative Neoplasms.
    Lin Y; Liu E; Sun Q; Ma J; Li Q; Cao Z; Wang J; Jia Y; Zhang H; Song Z; Ai X; Shi L; Feng X; Li C; Wang J; Ru K
    Am J Clin Pathol; 2015 Jul; 144(1):165-71. PubMed ID: 26071474
    [TBL] [Abstract][Full Text] [Related]  

  • 46. [Two myeloproliferative diseases in one patient - co-occurence of clones].
    Fekete S; Reichardt J; Kozma A; Kapócs K; Meggyesi N
    Orv Hetil; 2022 Jul; 163(28):1123-1129. PubMed ID: 35895464
    [TBL] [Abstract][Full Text] [Related]  

  • 47. [Clinical Analysis of Driver Mutations in Patients with Ph Negative Myeloproliferative Neoplasms].
    He ZP; Tian HY; Tan M; Wu Y
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2018 Jun; 26(3):842-848. PubMed ID: 29950230
    [TBL] [Abstract][Full Text] [Related]  

  • 48. [Diagnosis and treatment of BCR/ABL-negative myeloproliferative diseases--principles and rationale of CZEMP recommendations].
    Schwarz J; Penka M; Campr V; Pospísilová D; Kren L; Nováková L; Bodzásová C; Brychtová Y; Cerná O; Dulícek P; Joniásová A; Kissová J; Korístek Z; Schützová M; Vonke I; Walterová L
    Vnitr Lek; 2011 Feb; 57(2):189-213. PubMed ID: 21416861
    [TBL] [Abstract][Full Text] [Related]  

  • 49. The expression of Death Inducer-Obliterator (DIDO) variants in Myeloproliferative Neoplasms.
    Berzoti-Coelho MG; Ferreira AF; de Souza Nunes N; Pinto MT; Júnior MC; Simões BP; Martínez-A C; Souto EX; Panepucci RA; Covas DT; Kashima S; Castro FA
    Blood Cells Mol Dis; 2016 Jul; 59():25-30. PubMed ID: 27282563
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Comparison of FISH and quantitative RT-PCR for the diagnosis and follow-up of BCR-ABL-positive leukemias.
    Bao F; Munker R; Lowery C; Martin S; Shi R; Veillon DM; Cotelingam JD; Nordberg ML
    Mol Diagn Ther; 2007; 11(4):239-45. PubMed ID: 17705578
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Clinical and Molecular Attributes of Patients With BCR/ABL1-negative Myeloproliferative Neoplasms in India: Real-world Data and Challenges.
    Singh S; Kaur K; Paul D; Jain K; Singh J; Narang V; Garg B; Sood N; Dhillon B
    Clin Lymphoma Myeloma Leuk; 2021 Jun; 21(6):e569-e578. PubMed ID: 33757770
    [TBL] [Abstract][Full Text] [Related]  

  • 52. BCR-ABL1- positive chronic myeloid leukemia with erythrocytosis presenting as polycythemia vera: a case report.
    Cornea MI; Levrat E; Pugin P; Betticher DC
    J Med Case Rep; 2015 Apr; 9():30. PubMed ID: 26187587
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Genetic analysis of chromosome 13 deletions in BCR/ABL negative chronic myeloproliferative disorders.
    Pastore C; Nomdedeu J; Volpe G; Guerrasio A; Cambrin GR; Parvis G; Pautasso M; Daglio C; Mazza U; Saglio G
    Genes Chromosomes Cancer; 1995 Oct; 14(2):106-11. PubMed ID: 8527391
    [TBL] [Abstract][Full Text] [Related]  

  • 54. The co-occurrence of driver mutations in chronic myeloproliferative neoplasms.
    Boddu P; Chihara D; Masarova L; Pemmaraju N; Patel KP; Verstovsek S
    Ann Hematol; 2018 Nov; 97(11):2071-2080. PubMed ID: 29951914
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Clinical significance of dual color-dual fusion translocation fluorescence in situ hybridization in the detection of bcr/abl fusion gene.
    Wu B; Zhou S; Song L; Liu X
    Zhonghua Zhong Liu Za Zhi; 2002 Jul; 24(4):364-6. PubMed ID: 12408765
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Effect of CALR and JAK2 mutations on the clinical and hematological phenotypes of the disease in patients with myelofibrosis - long-term experience from a single center.
    Palova M; Szotkowski T; Hlusi A; Indrak K; Navratilova J; Divoka M; Papajik T
    Neoplasma; 2018; 65(2):296-303. PubMed ID: 29534592
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Chronic myeloid leukemia patient with co-occurrence of BCR-ABL junction and JAK2 V617F mutation.
    Xu W; Chen B; Tong X
    Int J Hematol; 2014 Jan; 99(1):87-90. PubMed ID: 24293258
    [TBL] [Abstract][Full Text] [Related]  

  • 58. A Case Report of
    Ali EAH; Al-Akiki S; Yassin MA
    Case Rep Oncol; 2021; 14(1):690-694. PubMed ID: 34054462
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Conformation sensitive gel electrophoresis for the detection of calreticulin mutations in BCR-ABL1-negative myeloproliferative neoplasms.
    Zakaria NA; Rosle NA; Siti Asmaa MJ; Aziee S; Haiyuni MY; Samat NA; Husin A; Hassan R; Ramli M; Mohamed Yusoff S; Ibrahim IK; Al-Jamal HAN; Johan MF
    Int J Lab Hematol; 2021 Dec; 43(6):1451-1457. PubMed ID: 34125992
    [TBL] [Abstract][Full Text] [Related]  

  • 60.
    Lighezan DL; Bojan AS; Iancu M; Pop RM; Gligor-Popa Ș; Tripon F; Cosma AS; Tomuleasa C; Dima D; Zdrenghea M; Fetica B; Ioniță I; Gaál IO; Vișan S; Mirea AM; Popp RA; Florea M; Araniciu C; Petrescu L; Pop IV; Bănescu C; Trifa AP
    J Pers Med; 2020 Dec; 10(4):. PubMed ID: 33271790
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.